Earlier surgery and regenerative recovery
Earlier intervention and regenerative recovery describe different decisions: whether surgery is appropriate now and whether an additional preparation has evidence for a specific recovery outcome.
Anatomy matters more than a milestone
A facelift or eyelid procedure should respond to the concern, anatomy, health and realistic expectations. There is no universal age at which lighter surgery becomes the right choice. A mini label still requires a clear explanation of the operation, anaesthesia, scars and recovery. Waiting or having no procedure remains an option.
A recovery signal needs its context
A randomized study in 20 women undergoing temple fat grafting found shorter recovery with added PRF but no significant improvement in retained fat volume. That result does not establish benefits for every facelift, eyelid operation or infusion. Ask whether the study matches the operation, preparation and route being offered.
Separate established care from added products
Exosomes should not be presented as a proven routine postoperative infusion. The U.S. FDA reports no approved exosome products and has issued a safety notice; status in another country must be checked separately. Discuss the evidence for any proposed adjunct, how it changes risks and cost and whether the surgeon’s standard recovery plan is sufficient.
“What supports having this operation now and what evidence shows the proposed recovery add-on improves this exact procedure?”
Read the original sources
Professional & regulatory sources
ASPS: facelift decisions, anatomy and age (2024) ASPS: facelift candidates and expectations FDA: safety notification on unapproved exosome productsPublished research
Zhang et al.: randomized PRF and temple fat-grafting trial (2022)General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.